Learn More
Leibniz University Hanover, Hanover, Germany; University of Bielefeld, Bielefeld, Germany; F. Hoffmann-La Roche AG, Basel, Switzerland; Techniker Krankenkasse, Hamburg, Germany; Bayer HealthCare AG,Wuppertal, Germany; Ludwig-Maximilians University, Munich, Germany; DAK-Unternehmen Leben, Hamburg, Germany; University of Erlangen-Nuremberg, Nuremberg,(More)
PURPOSE To estimate the cost-effectiveness from a French payer perspective of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) alone compared with CHOP plus rituximab (R-CHOP) for treatment of patients with diffuse large B-cell lymphoma. METHODS Mean patient survival, days of hospitalization, and chemotherapy costs during treatment were(More)
OBJECTIVE To assess the effects of treatment with rituximab plus methotrexate on patient-reported outcomes in patients with active rheumatoid arthritis (RA) who experienced inadequate response to anti-tumor necrosis factor therapy. METHODS Patients with active RA were randomly assigned to rituximab (1,000 mg on days 1 and 15) or placebo. The primary end(More)
OBJECTIVES The aim of this in vitro study was to examine the effect of different levels of magnification on the accuracy and reliability of visual caries detection using ICDAS criteria. METHODS Occlusal surfaces of 100 extracted molars were assessed by 14 examiners (3rd and the 4th year dental students and dentists) using no magnification aids, a 2.5×(More)
BACKGROUND To evaluate the impact of treatment on health states that affect patients' quality of life in advanced follicular lymphoma. METHODS A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008). RESULTS Cyclophosphamide, vincristine,(More)